Data from investigational uses of luspatercept-aamt included the initial results from a phase 2 study in myelofibrosis-associated anemia. Presentations also included updated results from two pivotal ...

Luspatercept-aamt improved red blood cell transfusion independence with a concurrent hemoglobin increase among certain patients with myelodysplastic syndrome, according to the agent’s manufacturer.

Bristol Myers Squibb Company BMY and partner Acceleron Pharma Inc. XLRN announced that the FDA has approved a label expansion of Reblozyl (luspatercept-aamt). The drug has been approved for the ...

This medication is used to treat anemia caused by certain blood and bone marrow disorders (such as beta thalassemia, myelodysplastic syndromes). In these conditions, your body does not make enough ...

Bristol Myers Squibb announced the withdrawal of the supplemental Biologics License Application (sBLA) for luspatercept-aamt, an erythroid maturation agent, for the treatment of anemia in adults with ...

Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) is approved as a first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes. Bristol Myers Squibb announced FDA approval of ...